ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag fda clinical trials biotech

How Vesselon Can Improve the Entire Class of Radiopharmaceuticals
Clayton Larsen - President & CEO, Vesselon, Inc. | Nov 21, 2023 | 3 min read
Vesselon's microspheres optimize radiopharmaceuticals for targeted treatment, enhancing anti-tumor effects.
How Vesselon Can Improve the Entire Class of Antibody-Drug Conjugates
Clayton Larsen - President & CEO, Vesselon, Inc. | Oct 30, 2023 | 4 min read
Vesselon’s novel co-formulation of gas lipid microspheres and self-assembling liposomes, targeted and activated by commercial ultrasound, would be an ideal adjunct to any of these ADC drugs.
A gloved hand holds a tweezer and pulls a section of DNA away from a double helix
First Person Dosed in Novel Gene Editing Clinical Trial
Amanda Heidt | Jul 12, 2022 | 4 min read
The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.
EXCLUSIVE
Colorful pills and capsules on a calendar background
Clinical Trial Registry Errors Undermine Transparency
Catherine Offord | Aug 2, 2022 | 10 min read
A lack of comprehension among some researchers about how to use ClinicalTrials.gov may be hindering public access to trial information and holding up drug study results, an investigation by The Scientist finds.
FDA OKs stem cell trial
Elie Dolgin | Jan 22, 2009 | 2 min read
California-based biotech company Geron Corp. announced today (Jan. 23) that it has received clearance from the U.S. Food and Drug Administration to begin trials for the world's first clinical study on human embryonic stem cell-based therapy. linkurl:Geron;http://www.geron.com/ plans to initiate a Phase I multicenter clinical trial in up to 10 patients paralyzed due to spinal cord injury. Its treatment -- currently referred to as "GRNOPC1" -- uses embryonic stem cells coaxed to become nerve cell
2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Cannabis Biotech
Daniel Cossins | Dec 1, 2014 | 8 min read
As medical marijuana businesses set up shop across the U.S., a handful of companies are taking the pharmaceutical route, guiding cannabis-derived drugs through clinical trials.
Synthetic Bacteria Help Treat Phenylketonuria in Mice
Diana Kwon | Aug 17, 2018 | 2 min read
The genetically engineered probiotic, already in clinical trials, may ease patients’ strict dietary regimes.

Run a Search

ADVERTISEMENT